Inclusion Criteria:

- 18 years of age or over

- Newly diagnosed lymphoma that would typically be treated with agents in the R-CHOP
regimen OR recurrent/progressive lymphoma in patients who were previously treated
with at least one drug in the R-CHOP regimen or bendamustine.

- At least one cancerous lymph node that is considered accessible for percutaneous
injection by the investigator and that is at least 2 cm in longest dimension.

- ECOG performance status of 0-2 (or a Karnofsky performance status of >50%).

- Labs required for enrollment: Absolute neutrophil count > 1000/mm3, platelet count >
50,000/mm3, hematocrit > 25%, and coagulation, liver and renal function tests within
normal limits.

Exclusion Criteria:

- Lymphoma patients in which the delay of up to 3 days to surgery or other factors
associated with the study are not feasible.

- Patients with central nervous system disease.

- Any therapy that is potentially immunosuppressive or has anticancer activity in the 4
weeks prior to device microinjection.

- Patients with active fungal, viral, or bacterial infections

- Pregnant women.

- Inability to give informed consent.